EVAN KOESLER: Open Payments
NPI 1780065755 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 30 payments from 11 companies in 2025. Trend: 2023 $140 · 2024 $25 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $192 |
| Novartis Pharmaceuticals Corporation | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $86 |
| Amgen Inc. | 3 | $50 |
| GENZYME CORPORATION | 1 | $30 |
| Grifols USA, LLC | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $21 |
| Organon LLC | 2 | $19 |
Products named: DUPIXENT, TEZSPIRE, FASENRA, CUVITRU, XOLAIR, Xembify, AIRSUPRA, NEFFY.
Industry payments across TX — which companies pay providers there.
